New Delhi: Bharat Biotech's intranasal Covid vaccine has received emergency-use approval from Drugs Controller General of India, officials said on Tuesday.
"Big Boost to India's Fight Against COVID-19! Bharat Biotech's ChAd36-SARS-CoV-S COVID-19 (Chimpanzee Adenovirus Vectored) recombinant nasal vaccine approved by @CDSCO_INDIA_INF for primary immunization against COVID-19 in 18+ age group for restricted use in emergency situation," Union Health Minister Dr Mansukh Mandaviya tweeted.
He said that the step will "further strengthen our collective fight against the pandemic." "India has harnessed its science, R&D, and human resources in the fight against COVID-19 under PM @NarendraModi Ji's leadership. With the science-driven approach & Sabka Prayas, we will defeat COVID-19," the minister said in a separate tweet.
Hyderabad-based Bharat Biotech International Limited (BBIL) completed clinical trials of the nasal vaccine with about 4,000 volunteers and there is no side effect or adverse reaction reported so far, company sources had said. In August, it said its COVID-19 intranasal vaccine (BBV154) has proven to be safe, well-tolerated, and immunogenic in subjects in controlled clinical trials phase -3.
Also read: Bharat Biotech, ExcellGene consortium to develop variant-proof Covid vax
BBV154 has been specifically formulated to allow intranasal delivery. In addition, the nasal delivery system has been designed and developed to be cost-effective in low and middle-income countries, the vaccine maker had said. "Being an intranasal vaccine, BBV154 may produce local antibodies in the upper respiratory tract. These may provide the potential to reduce infection and transmission. Further studies are being planned," the firm had said.
Two separate and simultaneous clinical trials were conducted to evaluate BBV154 as a primary dose (2-dose) schedule and a heterologous booster dose for subjects who have previously received 2 doses of the two commonly administered Covid vaccines -- Covishield and Covaxin -- in India.
Separately, the DCGI also granted permission to the firm to conduct phase-3 clinical trial to compare the immunogenecity and safety of BBV154 (intranasal) with Covaxin. This trial has been permitted to be conducted at nine sites. (Agency inputs)
